A ten-year study of 5-flurouracil in disseminated breast cancer with clinical results and survival times..

Abstract

The clinical results of 676 patients with widely disseminated breast cancer treated with 5-fluorouracil (5-FU) alone or with any additional therapy over the past ten years are presented. One observes a significantly increased survival in the 23.1 percent that improved and the 23.1 percent that were unchanged compared to the 53.8 percent that had progression on 5-FU therapy. To eliminate the beneficial influence on survival as a result of any other treatment, all patients who improved or were unchanged by other therapy were deleted, leaving a “corrected” group which showed a pattern almost identical to the overall total group, correlating increased survival with 5-FU responsiveness.